Y. Deniz - Regeneron Pharmaceuticals, Inc

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 76 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Effet à long terme du dupilumab sur la fonction respiratoire chez des patients pédiatriques souffrant d’asthme non contrôlé

L. Bacharier,A. Deschildre, T. Guilbert,A. Custovic,A. Altincatal,O. Ledanois,R. Gall,H. Sacks, J. Jacob-Nara,Y. Deniz, P. Rowe

Revue des Maladies Respiratoires Actualitésno. 1 (2024): 185

引用0浏览0引用

Efficacité du dupilumab chez des patients avec et sans réduction minimale importante de la fraction de monoxyde d’azote dans l’air expiré après 2 semaines

I. Pavord, L. Guilleminault,M. Wechsler,W. Busse, C. Domingo,C. Xia,R. Gall,N. Pandit-Abid,J. Jacob-Nara,A. Radwan, P. Rowe,Y. Deniz

Revue des Maladies Respiratoires Actualitésno. 1 (2024): 186

引用0浏览0引用

Improved Lung Function Is Associated With Better Asthma Control in Children With Moderate-to-Severe Type 2 Asthma: Voyage Study

L.B. Bacharier, S. Dell, I. De Mir-Messa, G. Piacentini,E. Hamelmann,J. Msihid,R. Gall,O. Ledanois, Z. Wang, W.W.-H. Cheng,H. Sacks, J.A. Jacob-Nara,

C34. BIOLOGIC THERAPY IN THE FIGHT AGAINST ASTHMA AND ALLERGIC INFLAMMATION (2024)

引用0浏览0引用

Dupilumab Add-on to Medium-dose Inhaled Corticosteroid (ICS) Increases Odds of Asthma Control and Reduces FeNO Compared With Placebo Add-on to High-dose ICS

W. Busse, M. Castro,N.L. Lugogo, P.M. O’Byrne,L.B. Bacharier, C. Xia, M. Hardin, M. Soliman,H. Sacks, J.A. Jacob-Nara,P.J. Rowe,Y. Deniz

C34. BIOLOGIC THERAPY IN THE FIGHT AGAINST ASTHMA AND ALLERGIC INFLAMMATION (2024)

引用0浏览0引用

CO174 Baseline Characteristics of Patients with Asthma and Prior Oral Systemic Corticosteroid Use Initiating Dupilumab in a Real-World Registry (RAPID)

NL. Lugogo, E. Heffler, V. Plaza, O. Hilberg,C. Xia, S. Nash,N.. Pandit-Abid,J.A.. Jacob-Nara,H. Sacks,PJ. Rowe,Y. Deniz,M. Hardin,

Value in Healthno. 6 (2024): S50

引用0浏览0引用

Évaluation de l’effet du dupilumab sur l’inflammation de type 2 des voies respiratoires et le bouchon de mucus chez les patients souffrant d’asthme modéré à sévère non contrôlé : l’essai VESTIGE

M. Castro, A. Papi,C. Porsbjerg,N.L. Lugogo,C.E. Brightling, F.J. González-Barcala, A. Bourdin, M. Ostrovskyy, M. Staevska, P.C. Chou, L. Duca, A.M. Pereira,

Revue Française d'Allergologie (2024)

引用0浏览0引用

Dupilumab long-term efficacy in patients with asthma with or without comorbid chronic rhinosinusitis/nasal polyposis enrolled in LIBERTY ASTHMA TRAVERSE from phase 2b study

P. Berger, A. Menzies-Gow,A. Peters,P. Kuna,K. F. Rabe, A. Artincatal,X. Soler,N. Pandit-Abid, S. Siddiqui,Y. Deniz, J. A. Jacob-Nara,P. J. Rowe

ALLERGOLOGIEno. 8 (2023): 5-5

引用0浏览0引用

Efficacy of dupilumab in patients with asthma stratified by a minimally important fractional exhaled nitric oxide reduction at week 2 of treatment

I. Pavord,M. Wechsler,W. W. Busse,C. Domingo,C. Xia,R. Gall,N. Pandit-Abid,J. A. Jacob-Nara, R. Amr,P. J. Rowe,Y. Deniz

ALLERGY (2023): 183-183

引用0浏览0引用

PCR200 Characteristics at Baseline of Patients with Asthma and Prior Systemic Corticosteroid Use Initiating Dupilumab Enrolled in the Real-World Study Rapid

N.L. Lugogo, E. Heffler, V. Plaza, O. Hilberg,C. Xia, S. Nash,N. Pandit-Abid, J.A. Jacob-Nara,H. Sacks,P.J. Rowe,Y. Deniz,M. Hardin,

Value in Healthno. 12 (2023): S487-S488

引用0浏览0引用

Long-term efficacy of dupilumab in patients with type 2 asthma by age at onset: LIBERTY ASTHMA TRAVERSE

W. W. Busse, M. Kraft,C. Domingo,I. De Mir, D. J. Maselli, X. Soler,C. Xia,N. Pandit-Abid,J. A. Jacob-Nara,H. Sacks,P. J. Rowe,Y. Deniz

ALLERGOLOGIE（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn